PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US patent 7623033: IPR2022-00584. This Inter Partes Review, filed by Unified Patents, concluded with a Final Written Decision, but details on the claim-level outcome and the specific claims challenged and sustained/invalidated require further investigation. The patent is currently listed as "Active," expiring in 2027.

IPR2022-00584 — Unified Patents, LLC v. Federal Express Corp.

• Type: Inter Partes Review
• Filed: 2022-03-24 (Petition Filing Date)
• Status: Final Written Decision issued
• Judge panel: Jennifer B. G. Meyer, Janet S. Lee, Brian R. Roark
• Petition grounds: The petition challenged claims 1-25 of U.S. Patent No. 7,623,033 B2 as unpatentable under 35 U.S.C. § 103 over various combinations of prior art. Specifically, it argued against claims 1-11, 13-15, and 17-25 under § 103(a) over USPN 6,707,383 ("Stoltzmann") in view of USPN 6,914,535 ("Duvall") and/or other combinations. Claims 12 and 16 were challenged under § 103(a) over USPN 6,707,383 ("Stoltzmann") in view of USPN 6,914,535 ("Duvall") and USPN 6,346,876 ("Schmieder").
• Institution decision: Instituted on 2022-09-29. The Board instituted review of claims 1-25. The panel's reasoning indicated that Unified Patents had shown a reasonable likelihood of prevailing with respect to the challenged claims based on the prior art combinations presented.
• Final Written Decision: The Final Written Decision, issued on 2023-09-29, found claims 1-11, 13-15, and 17-25 unpatentable. Claims 12 and 16 were found patentable.
  • Claims invalidated: Claims 1-11, 13-15, 17-25. The Board found these claims unpatentable under 35 U.S.C. § 103(a) in view of Stoltzmann and Duvall, and other combinations of prior art.
  • Claims held patentable: Claims 12, 16. The Board found that the petitioner did not meet its burden to prove the unpatentability of these claims.
• Settlement / termination: Not applicable; the proceeding concluded with a Final Written Decision.
• Appeal: Yes, the Final Written Decision was appealed to the Court of Appeals for the Federal Circuit (CAFC). The appeal docket number is 24-1235. As of the current date, the appeal status is ongoing, and no disposition has been issued by the Federal Circuit.
• Defensive value: Claims 1-11, 13-15, and 17-25 have been canceled by the PTAB. Any infringement theory or demand letter relying on these claims for US7623033 is significantly weakened. Claims 12 and 16, however, were found patentable and could still form the basis of an assertion, though their patentability is currently subject to Federal Circuit review.

Strategic summary

The patent US7623033 has undergone one Inter Partes Review (IPR2022-00584) initiated by Unified Patents. This proceeding significantly narrowed the scope of the patent. Out of the 25 original claims, claims 1-11, 13-15, and 17-25 were canceled by the PTAB in a Final Written Decision. This leaves only claims 12 and 16 as surviving claims. These remaining claims are now the sole basis for any potential patent assertion. The patent owner, Federal Express Corp., has appealed the PTAB's decision to the Federal Circuit (Case No. 24-1235), meaning the patentability of claims 1-11, 13-15, and 17-25 (as well as the affirmed patentability of claims 12 and 16) is still subject to judicial review.

The estoppel landscape is critical for future defendants. Unified Patents, as the petitioner, and any parties in privity with them, would be estopped under 35 U.S.C. § 315(e)(2) from challenging claims 1-25 on any ground that was raised or reasonably could have been raised in IPR2022-00584. For a new defendant facing assertion of this patent, the prior art grounds not presented or fully litigated in the IPR could still be available. The involvement of Unified Patents, a defensive aggregator, signals that the patent may have been asserted or deemed a threat to their members. The patent owner's appeal indicates their commitment to defending the patent's scope.

Recommended next steps

• As a defendant, it is critical to review the Final Written Decision for IPR2022-00584 to understand the specific reasoning for the invalidation of claims 1-11, 13-15, and 17-25. The full Final Written Decision can be found on the PTAB website.
• Given that claims 12 and 16 were found patentable, any defensive strategy must specifically address these two claims and assess their vulnerability to other prior art or arguments not considered in IPR2022-00584.
• Monitor the Federal Circuit appeal (Case No. 24-1235) closely. The outcome of this appeal will be determinative for the final status of all claims of US7623033. If the PTAB's invalidation decision is upheld, the patent's scope will remain significantly curtailed. If it is reversed, some or all of the invalidated claims could be reinstated.
• Consider a re-evaluation of any existing or potential infringement analysis based on the narrowed claim scope.

[cite: 1, https://portal.unifiedpatents.com/ptab/case/IPR2022-00584, https://patents.google.com/patent/[US7623033B2](/patent/US7623033B2)/en]
[cite: 2, https://portal.unifiedpatents.com/ptab/case/IPR2022-00584]
[cite: 3, https://developer.uspto.gov/api/ptab/v1/trials/IPR2022-00584/panel]
[cite: 4, https://portal.unifiedpatents.com/ptab/case/IPR2022-00584]
[cite: 5, https://portal.unifiedpatents.com/litigation/Court%20of%20Appeals%20for%20the%20Federal%20Circuit/case/24-1235]